Latest Insider Transactions at Nurix Therapeutics, Inc. (NRIX)
This section provides a real-time view of insider transactions for Nurix Therapeutics, Inc. (NRIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nurix Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nurix Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 30
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,387
-1.89%
|
$16,644
$12.04 P/Share
|
|
Apr 30
2024
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,886
+3.28%
|
-
|
|
Feb 16
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,812
-9.07%
|
$68,120
$10.02 P/Share
|
|
Jan 30
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,760
-9.17%
|
$12,320
$7.99 P/Share
|
|
Jan 30
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,924
+9.75%
|
-
|
|
Jan 30
2024
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,334
-6.03%
|
$16,338
$7.99 P/Share
|
|
Jan 30
2024
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,207
+6.47%
|
-
|
|
Jan 30
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,671
-2.18%
|
$11,697
$7.99 P/Share
|
|
Jan 30
2024
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,886
+3.13%
|
-
|
|
Dec 20
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,541
-4.69%
|
$35,410
$10.0 P/Share
|
|
Dec 19
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,906
-12.63%
|
$109,060
$10.0 P/Share
|
|
Oct 31
2023
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,633
-4.64%
|
$8,165
$5.2 P/Share
|
|
Oct 31
2023
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,232
-7.47%
|
$6,160
$5.2 P/Share
|
|
Oct 31
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,080
-1.23%
|
$5,400
$5.2 P/Share
|
|
Oct 30
2023
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,207
+7.1%
|
-
|
|
Oct 30
2023
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,924
+11.27%
|
-
|
|
Oct 30
2023
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,886
+2.75%
|
-
|
|
Jul 31
2023
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,884
-5.92%
|
$16,956
$9.65 P/Share
|
|
Jul 31
2023
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,420
-10.17%
|
$12,780
$9.65 P/Share
|
|
Jul 31
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,245
-1.49%
|
$11,205
$9.65 P/Share
|
|
Jul 30
2023
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,207
+7.81%
|
-
|
|
Jul 30
2023
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,924
+13.19%
|
-
|
|
Jul 30
2023
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,886
+2.87%
|
-
|
|
May 01
2023
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,136
-4.09%
|
$10,224
$9.88 P/Share
|
|
May 01
2023
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
682
-6.36%
|
$6,138
$9.88 P/Share
|
|
May 01
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
721
-0.91%
|
$6,489
$9.88 P/Share
|
|
May 01
2023
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
342
-5.3%
|
$3,078
$9.88 P/Share
|
|
Apr 30
2023
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,206
+10.35%
|
-
|
|
Apr 30
2023
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+15.21%
|
-
|
|
Apr 30
2023
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+3.5%
|
-
|
|
Apr 30
2023
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+12.97%
|
-
|
|
Jan 30
2023
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,412
-5.78%
|
$15,532
$11.78 P/Share
|
|
Jan 30
2023
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,207
+11.61%
|
-
|
|
Jan 30
2023
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
848
-10.46%
|
$9,328
$11.78 P/Share
|
|
Jan 30
2023
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+19.18%
|
-
|
|
Jan 30
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
924
-1.19%
|
$10,164
$11.78 P/Share
|
|
Jan 30
2023
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+3.58%
|
-
|
|
Jan 30
2023
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
424
-9.72%
|
$4,664
$11.78 P/Share
|
|
Jan 30
2023
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+18.06%
|
-
|
|
Oct 31
2022
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
350
-9.33%
|
$4,200
$12.88 P/Share
|
|
Oct 31
2022
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,165
-5.21%
|
$13,980
$12.88 P/Share
|
|
Oct 31
2022
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
699
-10.15%
|
$8,388
$12.88 P/Share
|
|
Oct 31
2022
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
739
-0.98%
|
$8,868
$12.88 P/Share
|
|
Oct 30
2022
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+20.41%
|
-
|
|
Oct 30
2022
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,207
+12.53%
|
-
|
|
Oct 30
2022
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+21.84%
|
-
|
|
Oct 30
2022
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+3.68%
|
-
|
|
Aug 01
2022
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
712
-13.37%
|
$10,680
$15.67 P/Share
|
|
Aug 01
2022
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
356
-22.33%
|
$5,340
$15.67 P/Share
|
|
Aug 01
2022
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
752
-1.02%
|
$11,280
$15.67 P/Share
|